The implications of different approaches to define AT(N) in Alzheimer disease.
Aged
Alzheimer Disease
/ classification
Amyloid beta-Peptides
/ cerebrospinal fluid
Aniline Compounds
/ metabolism
Benzothiazoles
/ metabolism
Biomarkers
/ cerebrospinal fluid
Brain
/ metabolism
Carbolines
/ metabolism
Case-Control Studies
Cognitive Dysfunction
/ epidemiology
Female
Humans
Longitudinal Studies
Male
Mental Status and Dementia Tests
/ statistics & numerical data
Middle Aged
Nerve Degeneration
/ epidemiology
Neurofilament Proteins
/ cerebrospinal fluid
Positron-Emission Tomography
Sweden
/ epidemiology
tau Proteins
/ cerebrospinal fluid
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
26 05 2020
26 05 2020
Historique:
received:
28
08
2019
accepted:
19
12
2019
pubmed:
14
5
2020
medline:
22
9
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
To compare different β-amyloid (Aβ), tau, and neurodegeneration (AT[N]) variants within the Swedish BioFINDER studies. A total of 490 participants were classified into AT(N) groups. These include 53 cognitively unimpaired (CU) and 48 cognitively impaired (CI) participants (14 mild cognitive impairment [MCI] and 34 Alzheimer disease [AD] dementia) from BioFINDER-1 and 389 participants from BioFINDER-2 (245 CU and 144 CI [138 MCI and 6 AD dementia]). Biomarkers for A were CSF Aβ Among CU participants, A-T-(N)- or A+T-(N)- variants were most common. However, more T+ cases were seen using p-tau than tau PET. Among CI participants, A+T+(N)+ was more common; however, more (N)+ cases were seen for MRI measures relative to CSF NfL. Tau PET best predicted longitudinal cognitive decline in CI and p-tau in CU participants. Among CI participants, continuous T (especially tau PET) and (N) measures improved the prediction of cognitive decline compared to binary measures. Our findings show that different AT(N) variants are not interchangeable, and that optimal variants differ by clinical stage. In some cases, dichotomizing biomarkers may result in loss of important prognostic information.
Identifiants
pubmed: 32398359
pii: WNL.0000000000009485
doi: 10.1212/WNL.0000000000009485
pmc: PMC7357296
doi:
Substances chimiques
Amyloid beta-Peptides
0
Aniline Compounds
0
Benzothiazoles
0
Biomarkers
0
Carbolines
0
Neurofilament Proteins
0
neurofilament protein L
0
tau Proteins
0
flutemetamol
0F3M7032P5
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
J09QS3Z3WB
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2233-e2244Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Acta Neuropathol Commun. 2019 Jan 9;7(1):5
pubmed: 30626432
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neurology. 2018 Jan 23;90(4):e282-e290
pubmed: 29282337
Brain. 2015 Mar;138(Pt 3):772-83
pubmed: 25541191
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1152-1163
pubmed: 30610252
JAMA Neurol. 2018 May 1;75(5):536-538
pubmed: 29435570
Science. 2018 Dec 14;362(6420):1250-1251
pubmed: 30545877
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
Ann Neurol. 2016 Aug;80(2):247-58
pubmed: 27323247
EMBO Mol Med. 2017 Sep;9(9):1212-1223
pubmed: 28743782
JAMA Neurol. 2019 Feb 1;76(2):187-193
pubmed: 30419087
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Arch Neurol. 2011 Aug;68(8):1040-8
pubmed: 21825241
Lancet Neurol. 2003 Oct;2(10):605-13
pubmed: 14505582
Acta Neuropathol. 2018 Dec;136(6):821-853
pubmed: 30488277
Nat Commun. 2016 Mar 07;7:10918
pubmed: 26948379
Neurology. 2017 Nov 21;89(21):2167-2175
pubmed: 29070659
Alzheimers Dement (Amst). 2018 Apr 21;10:346-357
pubmed: 30175226
JAMA Neurol. 2016 Jan;73(1):60-7
pubmed: 26524180
Nat Rev Neurol. 2010 Mar;6(3):131-44
pubmed: 20157306
Nat Commun. 2017 Oct 31;8(1):1214
pubmed: 29089479
JAMA Neurol. 2014 Oct;71(10):1282-9
pubmed: 25155658
J Nucl Med. 2018 Dec;59(12):1877-1884
pubmed: 30097505
Brain. 2015 Dec;138(Pt 12):3747-59
pubmed: 26428666
JAMA Neurol. 2019 Mar 1;76(3):318-325
pubmed: 30508027
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Sci Rep. 2016 May 31;6:26801
pubmed: 27241045
Neurology. 2015 Feb 10;84(6):617-22
pubmed: 25589671
Neurology. 2014 Nov 18;83(21):1945-53
pubmed: 25339208
Ann Neurol. 2016 Jan;79(1):110-9
pubmed: 26505746
J Alzheimers Dis. 2011;25(3):445-53
pubmed: 21471646
Brain. 2016 Apr;139(Pt 4):1226-36
pubmed: 26936941
J Nucl Med. 2017 Apr;58(4):623-631
pubmed: 27765859
Alzheimers Dement. 2018 Jul;14(7):869-879
pubmed: 29580670
Am J Alzheimers Dis Other Demen. 2019 Feb;34(1):16-22
pubmed: 30103612
Neurology. 2017 May 9;88(19):1814-1821
pubmed: 28404803
JAMA. 2015 May 19;313(19):1924-38
pubmed: 25988462